Serum paraoxonase/arylesterase activity affects outcome in ischemic stroke patients

Cerebrovascular Diseases

Volumn 32, Issue 2, 2011, Pages 124-132

  Michalak, Slawomir ^a   Kazmierski, Radoslaw ^a   Hellmann, Agnieszka ^a   Wysocka, Ewa ^b   Kocialkowska Adamczewska, Dagmara ^a   Wencel Warot, Agnieszka ^a   Nowinski, Wiesław L ^c  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b University of Medical Sciences   (Poland)

^c AGENCY FOR SCIENCE   (Singapore)

Author keywords

Arylesterase; Conjugated dienes; Ischemic stroke; Outcome; Paraoxonase

Indexed keywords

ALKADIENE; ARYLDIALKYLPHOSPHATASE; ARYLESTERASE;

AGED; ARTICLE; BARTHEL INDEX; BRAIN ISCHEMIA; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HOMEOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANKIN SCALE; SPECTROPHOTOMETRY; STROKE PATIENT; VITAL SIGN;

AGED; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CARBOXYLIC ESTER HYDROLASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; STROKE;

EID: 79960486320     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000328227     Document Type: Article

References (41)

1. Traystamn RJ, Kirsch JR, Koehler RC: Oxygen radical mechanism of brain injury following ischaemia and reperfusion. J Appl Physiol 1991; 71: 1185-1195.
2. Gariballa SE, Hutchin TP, Sinclair AJ: Antioxidant capacity after acute ischaemic stroke. Q J Med 2002; 95: 685-690. (Pubitemid 35203637)
3. Spranger M, Krempien S, Schwab S, Donnenberg S, Hacke W: Superoxide dismutase activity in serum of patients with acute cerebral ischemic injury: Correlation with clinical course and infarct size. Stroke 1997; 28: 2425-2428. (Pubitemid 28007644)
4. Cherubini A, Polidori MC, Bregnocchi M, Pezzuto S, Cecchetti R, Ingegni T, di Iorio A, Senin U, Mecocci P: Antioxidant profile and early outcome in stroke patients. Stroke 2000; 31: 2295-2300.
5. Kim NS, Kang K, Cha MH, Kang BJ, Moon J, Kang BK, Yu BC, Kim YS, Choi SM, Bang OS: Decreased paraoxonase-1 activity is a risk factor for ischemic stroke in Koreans. Biochem Biophys Res Commun 2007; 364: 157-162. (Pubitemid 47599458)
6. Ferretti G, Bacchetti T, Masciangelo S, Nanetti L, Mazzanti L, Silvestrini M, Bartolini M, Provinciali L: Lipid peroxidation in stroke patients. Clin Chem Lab Med 2008; 46: 113-117.
7. Aldridge WN: Serum esterases I. Biochem J 1953; 53: 110-117.
8. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M: Protective effect of high density lipoprotein associated paraoxonase: Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96: 2882-2891.
9. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, Fogelman AM, Reddy ST: Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell mediated oxidative modification of low density lipoprotein. J Biol Chem 2001; 276: 44444-44449.
10. Ranade K, Kirchgessner TG, Iakoubova OA, Devlin JJ, DelMonte T, Vishnupad P, Hui L, Tsuchihashi Z, Sacks FM, Sabatine MS, Braunwald E, White TJ, Shaw PM, Dracopoli NC: Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke. Stroke 2005; 36: 2346-2350. (Pubitemid 41566956)
11. Augustinsson K-B: Multiple forms of esterase in vertebrate plasma. Ann NY Acad Sci 1961; 94: 844-849.
12. Eckerson HW, Wyte CM, La Du BN: The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126-1128.
13. Kelly PJ, Morrow JD, Ning MM, Koroshetz W, Lo EH, Terry E, Milne GL, Hubbard J, Lee H, Stevenson E, Lederer M, Furie KL: Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: The Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) Study. Stroke 2008; 39: 100-104.
14. Shinohara Y, Saito I, Kobayashi S, Uchiyama S: Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet agent) in acute noncardioembolic ischemic stroke (EDO trial). Cerebrovasc Dis 2009; 27: 485-492.
15. Garbagnati F, Cairella G, De Martino A, Multari M, Scognamiglio U, Venturiero V, Paolucci S: Is antioxidant and n-3 supplementation able to improve functional status in poststroke patients? Results from the Nutristroke Trial. Cerebrovasc Dis 2009; 27: 375-383.
16. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parma SL, La Du BN: Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581-1590. (Pubitemid 28198486)
17. Gan KN, Smolen A, Eckerson HW, La Du BN: Purification of human serum paraoxonase/ arylesterase. Drug Metab Dispos 1991; 19: 100-106.
18. Recknagel RO, Glende EA: Spectrophotometric detection of lipid conjugated diens. Methods Enzymol 1984; 105: 331-337. (Pubitemid 14165395)
19. Kissela B, Lindsell CJ, Kleindorfer D, Alwell K, Moomaw Ch, Woo D, Flaherty M, Air E, Broderick J, Tsevat J: Clinical prediction of functional outcome after ischemic stroke: The surprising importance of periventricular white matter disease and race. Stroke 2009; 40: 530-536.
20. Whiteley W, Jackson C, Lewis S, Lowe G, Rumley A, Sandercock P, Wardlaw J, Dennis M, Sudlow C: Inflammatory markers and poor outcome after stroke: A prospective cohort study and systematic review of interleukin-6. PLoS Med 2009; 6:e1000145.
21. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C: Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 337: 1521-1526.
22. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd: Classification of subtype of acute ischemic stroke: Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41. (Pubitemid 23014379)
23. Voetsch B, Benke KS, Panhuysen CI, Damasceno BP, Loscalzo J: The combined effect of paraoxonase promoter and coding region polymorphisms on the risk of arterial ischemic stroke among young adults. Arch Neurol 2004; 61: 351-356. (Pubitemid 38327352)
24. Costa LG, Cole TB, Jarvik GP, Furlong CE: Functional genomics of the paraoxonase (PON1) gene polymorphisms: Effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 2003; 54: 371-382.
25. James RW, Leviev I, Righetti A: Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 2000; 101: 2252-2257. (Pubitemid 30317126)
26. Erguder IB, Erguder T, Ozkan C, Bozkurt N, Soylu K, Devrim E, Durak I: Short-term effects of smoking cessation on blood antioxidant parameters and paraoxonase activity in healthy asymptomatic long-term cigarette smokers. Inhal Toxicol 2006; 18: 575-579. (Pubitemid 43977253)
27. Deakin S, Moren X, James RW: Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells. Atherosclerosis 2005; 179: 17-25. (Pubitemid 40249782)
28. Davies H, Richter RJ, Keifer M, Broomfield C, Sowalla J, Furlong CE: The effect of human serum paraoxonase polymorphism is reversed with diazoxon, soman, and sarin. Nat Genet 1996; 14: 334-336.
29. Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, La Du BN: Human serum paraoxonase (PON1) isoenzymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 2000; 28: 1335-1342.
30. Mannheim D, Herrmann J, Versari D, Gössl M, Meyer FB, McConnell JP, Lerman LO, Lerman A: Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke 2008; 39: 1448-1455.
31. Li ZG, Yu ZC, Wang DZ, Ju WP, Zhan X, Wu QZ, Wu XJ, Cong HM, Man HH: Influence of acetylsalicylate on plasma lysophosphatidic acid level in patients with ischemic cerebral vascular diseases. Neurol Res 2008; 30: 366-369. (Pubitemid 351881288)
32. Park CH, Nguyen SD, Kim MR, Jeong TS, Sok DE: Differential effect of lysophospholipids on activities of human plasma paraoxonase1, either soluble or lipid-bound. Lipids 2006; 41: 371-380. (Pubitemid 43902266)
33. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, Erogul J, Hsu C, Dunlop C, Du BL: Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/ paraoxonase activities. Selective Action of Human Paraoxonase Allozymes Q and R. Arterioscler Thromb Vasc Biol 1998; 18: 1617-1624. (Pubitemid 28465415)
34. Tomás M, Sentí M, García-Faria F, Vila J, Torrents A, Covas M, Marrugat J: Effect of simvastatin therapy on paraoxonase activi -ty and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2000; 20: 2113-2119.
35. Sutherland W, Manning PJ, de Jong SA, Allum AR, Jones SD, Williams SM: Hormonereplacement therapy increases serum paraoxonase arylesterase activity in diabetic postmenopausal women. Metabolism 2001; 50: 319-324. (Pubitemid 32248979)
36. Catakay U, Kayali R, Uzun H: Relation of plasma protein oxidation parameters and paraoxonase activity in the ageing population. Clin Exp Med 2008; 8: 51-57. (Pubitemid 351666852)
37. Seres I, Paragh G, Deschene E, Fulop T Jr, Khalil A: Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp Gerontol 2004; 39: 59-66. (Pubitemid 38068260)
38. Murin R, Drgova A, Kaplan P, Dobrota D, Lehotsky J: Ischemia/reperfusion- induced oxidative stress causes structural changes of brain membrane proteins and lipids. Gen Physiol Biophys 2001; 20: 431-438. (Pubitemid 34196159)
39. Allen BS, Castellá M, Buckberg GD, Tan Z: Conditioned blood reperfusion markedly enhances neurologic recovery after prolonged cerebral ischemia. J Thorac Cardiovasc Surg 2003; 126: 1851-1858. (Pubitemid 38020742)
40. Barber PA, Davis SM, Infeld B, Baird AE, Donnan GA, Jolley D, Lichtenstein M: Spontaneous reperfusion after ischemic stroke is associated with improved outcome. Stroke 1998; 29: 2522-2528. (Pubitemid 28544002)
41. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, Furlong CE: Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1 192 or PON1 55 genotype. Arterioscler Thromb Vasc Biol 2000; 20: 2441-2447.